501423

- Schedule of Analyst / Institutional Investor Meeting - Meeting Date: 21st August 2026 - Meeting Time: 10:00 AM onwards - Nature of Meeting: Group Meeting - Venue: Baroda, Gujarat

- Q1 FY27 Consolidated Revenue ₹281Cr vs ₹247Cr (▲14% YoY) - EBITDA ₹83Cr vs ₹70Cr (▲18% YoY), EBITDA Margin 29.7% vs 28.3% (▲120bps) - PAT ₹48Cr vs ₹41Cr (▲17% YoY), PAT Margin 17.1% vs 16.6% (▲40bps) - Healthcare segment revenue grew 85% YoY to ₹142Cr, becoming 51% of consolidated revenue. - Industrial segment revenue grew 25% YoY to ₹23Cr. - Consumer segment revenue declined 24% YoY to ₹116Cr due to softer demand in Europe and US. Management expects this segment to maintain FY26 levels this year. - Additional 25 million pen capacity expected operational by end of September 2026, increasing total installed capacity to ~75 million pens per annum. - Management expects to exceed the full year pen guidance of 36 million. - Gross margins, which saw a sequential decline due to commodity and freight prices, are expected to normalize by Q3 FY27. - Actively working on new healthcare products: emergency use auto-injectors (closure by end of FY27), reusable auto-injectors (launching by year-end), and on-body injectors. - Secured first tentative U.S. FDA approval for generic Semaglutide and launched in multiple markets. - Appointed business development heads for Europe and North America to secure partnerships with major global pharmaceutical companies (announcement expected in 4-6 quarters for innovator segment). - Won a global project from an FMCG customer and new business in LED lighting; secured new projects from Appliance & Automotive customers and onboarded a new customer for 5 Consumer Electronic components. - Planning investment of ₹5Cr in existing facility for Semiconductor Trays and ₹80-100Cr for a new Consumer Electronics plant in South India. - Approximately 50-55% of the Abu Dhabi plant capacity is committed, with the plant expected to commence sales by end of FY28.

- Audio recording of the Earnings Call held on 10th August 2026 is available on the company website. The transcript will be submitted separately.

- Board approved unaudited Standalone & Consolidated Financial Results for the quarter ended June 30, 2026. - Re-appointed Mr. Amit Mahendra Sanghvi as Managing Director for a term of 5 years, effective October 1, 2026, to September 30, 2031. - Fixed September 11, 2026, as the Record Date for determining members entitled to receive the final dividend for FY 2025-26. - Approved revised Code of Conduct for Prevention of Insider Trading.

- Board meeting held on August 08, 2026, approved Unaudited Standalone & Consolidated Financial Results for the quarter ended June 30, 2026. - Re-appointed Mr. Amit Mahendra Sanghvi as Managing Director from October 01, 2026, to September 30, 2031. - Fixed September 11, 2026, as the Record Date for the final dividend for FY 2025-26. - Approved the revised Code of Conduct for Prevention of Insider Trading.

- Board approved Q1 FY27 (June 30, 2026) Unaudited Standalone & Consolidated Financial Results. - Fixed September 11, 2026, as Record Date for final dividend for FY 2025-26. - Approved re-appointment of Mr. Amit Mahendra Sanghvi as MD (Oct 1, 2026 - Sep 30, 2031), subject to shareholder approval.

- Q1 FY27 Consolidated Revenue ₹280.7Cr vs ₹246.7Cr (▲14% YoY) - EBITDA ₹83.3Cr vs ₹70.4Cr (▲18% YoY) - PAT ₹48.0Cr vs ₹41.1Cr (▲17% YoY) - EBITDA Margin 29.7% vs 28.5% (▲120bps) - Healthcare segment revenue grew by 85% YoY, driving overall growth. - Received customer approvals for Semaglutide pens in Canada/Brazil and new projects in IP-led platforms. - Secured a global project from an FMCG customer and new projects in LED lights. - Confirmed new projects from Appliance and Automotive customers and five new parts for Consumer Electronics.

- Q1 FY27 Consolidated Revenue ₹280.57 Cr vs ₹246.69 Cr (▲13.73% YoY) - EBITDA ₹83.05 Cr vs ₹68.40 Cr (▲21.42% YoY) - PAT ₹48.01 Cr vs ₹41.12 Cr (▲16.76% YoY) - EBITDA Margin 29.60% vs 27.73% (▲187 bps)

- Q1 FY27 Consolidated Revenue ₹280.57Cr vs ₹246.69Cr (▲14% YoY) - EBITDA ₹83.30Cr vs ₹70.49Cr (▲18% YoY) - PAT ₹48.01Cr vs ₹41.12Cr (▲17% YoY) - EBITDA Margin 29.7% vs 28.6% (▲110bps) - Record Date: September 11, 2026, for final dividend for FY 2025-26. - Mr. Amit Mahendra Sanghvi re-appointed as Managing Director for 5 years (Oct 2026 - Sep 2031). - Board approved revised Code of Conduct for Prevention of Insider Trading.

- Concall Schedule - Concall Date: 10th August 2026 - Concall Time: 4:00 PM, IST - Purpose: To discuss Q1 FY27 financial performance (quarter ended June 30, 2026).

- Board meeting on August 8, 2026, to approve Q1 FY27 financial results (quarter ended June 30, 2026). - Trading window closure from July 1, 2026, to August 10, 2026. - Company to publish financial results in Crores instead of Lacs, effective Q1 FY27.

- Concall Schedule - Concall Date: 13th & 14th July 2026 - Concall Time: 10:00 AM to 6:00 PM - Additional details: 1x1/Group Meetings organised by UBS in London, UK.

- Trading window for insiders to close from July 01, 2026. - Reopens 48 hours post declaration of Unaudited Financial Results for quarter ending June 30, 2026. - Board Meeting date for results will be intimated separately.

- Promoter group member, Vanita L. Nagda, disposed of 1,043,510 equity shares (2.27% of total equity) of Shaily Engineering Plastics Ltd. - The sale was conducted via Open Market on June 18, 2026.

- Investor Meeting Schedule - Meeting Date: 16th June 2026 - Meeting Time: 10:00 AM to 6:00 PM - Venue: Taj Santacruz, Mumbai - Organized by: Systematix